arGEN-X Appoints Dr Werner Lanthaler to its Supervisory Board
Breda, The Netherlands / Ghent, Belgium– arGEN-X, a clinical stage human therapeutic antibody company, announces that it has appointed Dr. Werner Lanthaler to its Supervisory Board.
Dr. Lanthaler has an outstanding track record of building and growing life sciences companies. He is currently Chief Executive Officer of Evotec (Frankfurt Stock Exchange: EVT), a role he took in March 2009. Under his leadership Evotec has become one of the leading drug discovery research organisations globally.
Before that, he spent nine years as Chief Financial Officer at Intercell AG (2000-2009). During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine and antibody player. Dr. Lanthaler played a pivotal role in many of the company's major corporate milestones including the product approval of Intercell's Japanese Encephalitis Vaccine, the company's acquisitions and strategic pharma partnerships, as well as the company's Initial Public Offering in 2005.
From 1998 to 2000, Dr. Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company. He holds a doctorate in Business Administration from Vienna University of Economics and Business, earned a Master's degree from Harvard University, and holds a degree in Psychology.
Peter Verhaeghe, Chairman of the arGEN-X Board said: I am delighted to welcome Werner to the arGEN-X Supervisory Board. His experience in building successful life sciences companies, and impressive business and corporate development track record will prove highly instrumental in the Company’s move to the next level of success.